Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2017

View Archived Issues

Denovo Biopharma will evaluate enzastaurin in biomarker-guided phase III study

Lucinactant shows favorable activity against bird flu in preclinical proof-of-concept study

Sobi adds rFIXFc-XTEN to its collaboration agreement with Bioverativ

Phase III SUNBEAM trial of oral ozanimod in patients with RMS meets primary endpoint

HSR clearance for collaboration and license agreement between Momenta and CSL

Oxidized form of membrane-bound vimentin as novel noninvasive biomarker of senescence

Small molecule UPC-K-005 acts through a novel inhibitory allosteric site in p38alpha

OlympiAD study supports utility of Myriad's BRACAnalysis CDx test in breast cancer

Takeda completes acquisition of Ariad Pharmaceuticals

Clinical data show malaria vaccine candidate PfSPZ-CVac is safe and efficacious

METIV-HCC phase III trial of tivantinib in HCC fails to meet primary endpoint

Toyama Chemical, Fujifilm identify novel C-X-C motif chemokine 10 inhibitors

Progenra describes new USP7/USP47 inhibitors

Immune Pharmaceuticals plans pivotal study of Ceplene in AML to support U.S. approval

Shire reflects on progress during fourth quarter of 2016

Grants supports work at University of Florida on improved Zika diagnostics

Kalytera Therapeutics completes acquisition of Talent Biotechs

Faron initiates phase II trial of Traumakine in patients with RAAA

EGFR(V)-EDV-dox nanocells carrying doxorubicin receives FDA orphan drug designation

Modus Therapeutics completes financing to support phase II trial of sevuparin

Autologous adipose-derived stromal vascular fraction cells studied in patients with Crohn's fistulas

EMA accepts Mereo's BPS-804 for Adaptive Pathways program

MIR17 family found to be a promising target for treating polycystic kidney disease

AstraZeneca licenses Zoladex commercial rights to TerSera in U.S. and Canada

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...